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Introduction: Molecular testing for epidermal growth factor recep-
tor (EGFR) and KRAS mutations is of increasing clinical importance
in daily practice. In this study, we aimed to investigate the yield and
applicability of molecular testing for KRAS and EGFR mutations in
cytologic specimens obtained by EUS or endobronchial ultrasound
(EBUS)-guided fine needle aspiration (FNA).
Methods: We selected all patients with an EUS- or EBUS-guided
FNA positive for lung adenocarcinoma from the database of our
tertiary care center for endosonography. Direct smears were Giemsa
and Papanicolaou stained. The remaining material was processed in
cell blocks. Both cell blocks and smears were considered suitable for
molecular analysis when40% of the aspirated cells were tumor cells.
All eligible samples were investigated for KRAS and EGFR mutations
by polymerase chain reaction followed by direct sequencing.
Results: Four hundred sixty-two patients underwent EUS or
EBUS-FNA using 22-gauge needles.
In 35 patients, FNA showed lung adenocarcinoma. In eight
patients, molecular analysis could not be performed because of insuf-
ficient material after routine and immunocytochemistry (n  3), a low
percentage (40%) of tumor cells (n 3), or an insufficient DNA quality
(n  2). The average percentage of tumor cells was 73%  23%.
Molecular analysis could reliably be performed in 27 patients (77%).
Mutation analysis showed KRAS and EGFR mutations in tumor sam-
ples from 10 (37%) and two (7%) patients, respectively. In one patient,
two EGFR mutations (p.Thr790Met and p.Leu858Arg) were detected.
Conclusions: Molecular analysis for KRAS and EGFR mutations
can be performed routinely in cytologic specimens from EUS- and
EBUS-guided FNA.
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Determination of the mutation status of the epidermalgrowth factor receptor (EGFR) gene is of importance to
adequately select patients with both early and advanced
non-small cell lung cancer (NSCLC) for targeted treatment
with tyrosine kinase inhibitors (TKIs) or monoclonal antibod-
ies and to predict the prognosis and response to EGFR-
targeted treatment and systemic chemotherapy.1–3 Also, the
KRAS mutational status is of importance because KRAS is an
important proliferation step downstream of the EGFR and
mutations in KRAS relate to resistance to EGFR-targeted
therapy and adjuvant chemotherapy.2,4,5 KRASmutations may
also be of relevance to other downstream pathways such as
the PI3K/AKT pathway.2,6
Recent landmark studies investigating the effects of
different TKIs in NSCLC used histologic specimens for
molecular analysis of the mutation status. However, in clin-
ical practice, the diagnosis of lung cancer is often based on
cytologic specimens because tissue samples are increasingly
obtained by ultrasound-guided techniques and on transtho-
racic fine needle aspirations (FNAs). Recent developments
have shown that transesophageal ultrasound-guided (EUS)
FNA (EUS-FNA) and endobronchial ultrasound (EBUS)-
guided FNA are minimally invasive diagnostic and staging
procedures, which have shown to be highly sensitive and
accurate.7–9 They allow safe cytologic sampling of mediasti-
nal lymph nodes and centrally located intrapulmonary tumors
or metastases in the upper abdomen including the left adrenal
gland. Therefore, EUS-FNA and EBUS have been incorpo-
rated in the guidelines of the European Society of Thoracic
Surgeons and American College of Chest Physicians,10,11 and
a combination of these techniques has been shown to have a
better sensitivity and negative predictive value than cervical
mediastinoscopy (the now debated gold standard).9,12
However, in contrast to cervical mediastinoscopy,
EUS-FNA and EBUS will result in cytologic specimens,
preferably processed on slides for rapid onsite evaluation and
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vials for cell blocks. Because these samples are often the only
available proof of lung cancer, mutation analysis performed
on cytologic specimens is of increasing interest.13 Further-
more, differences in mutations in the primary tumor site
compared with metastatic disease sites have been shown and
may be of importance to daily clinical practice.14 Therefore,
in case of recurrent disease, renewed tissue sampling needs to
be considered increasing the necessity to use minimal inva-
sive techniques for sampling of tumor material on which
molecular analyses can be performed.
Recently, two studies reported on EGFR analysis in cell
block-based cytologic specimens from EBUS.15,16 In this study,
we aimed to investigate the yield and applicability of molecular
testing for both KRAS and EGFR mutations in all available
cytologic specimens, both cell blocks and direct smears, obtained by
EUS-FNA- or EBUS-guided FNA in routine daily practice.
METHODS
Between January 2006 and January 2010, 462 patients
were evaluated in our tertiary care university hospital center
for endosonography. EUS was available since December
2005 and EBUS from December 2008 onward. Of these 462
patients, 289 were referred for diagnosis or staging of proven
or suspected lung cancer.
All patients were investigated in an outpatient proce-
dure using midazolam (2.5–5 mg) for conscious sedation.
EUS and EBUS were performed using Pentax EG 3870UTK
or EB-1970UK echo endoscopes in combination with a Hi-
tachi EUB 6500 or 7000HV ultrasound scanner. In all pa-
tients, FNA was performed using 22-gauge needles (Medi-
Globe); on average 2.9  1.1(standard deviation; range: 1–5)
aspirations per diagnostic site were performed. Direct smears
were made for Giemsa staining and Papanicolaou staining.
Giemsa-stained smears were processed and analyzed onsite
for rapid onsite evaluation by a cytotechnician. The remain-
ing material was processed in cell blocks, from which 4-m
slides were cut for hematoxylin and eosin staining and im-
munocytochemistry. To minimize the chance of false-nega-
tive results, on the basis of our experience in histologic
NSCLC and colorectal cancer specimens,17 both cell blocks
and smears were considered suitable for molecular analysis
when DNA could be isolated from regions with 40% tumor
cells. For DNA isolation from the cell blocks, the relevant
regions were manually microdissected from two to three
20-m sections using flanking hematoxylin and eosin-stained
slides as a reference and incubated overnight at 56°C in 200
l lysis buffer (10 mM Tris pH 8.5, 1 mM ethylenediami-
netetraacetic acid (EDTA); 0.05% tween20, 5% Chelex-100,
and 2 g/l Proteinase K) followed by 10 minutes at 95°C.
After centrifugation, the supernatant is used for subsequent
analyses. For the DNA isolation from the smears, regions
with more than 40% tumor cells are scraped from the glass
slides and incubated overnight at 56°C in 400 l lysis buffer
(10 mM Tris pH7.5, 2 mM EDTA, 400 mM NaCl, 1%
sodiumdodecylsulfate, and 2 g/l Proteinase K) followed
by a salt precipitation with 140 l 6 M NaCl and ethanol
precipitation of the supernatant. The DNA pellet is dissolved
in 20 l Tris (10 mM Tris pH 7.5 and 1 mM EDTA).
Mutation analysis of EGFR exons 18, 19, 20, and 21 and
KRAS codons 12, 13, and 61 was performed using 1 l DNA
solution in polymerase chain reactions (PCRs) followed by
Big-Dye terminator sequencing (BigDye Terminators (v 1.1);
Applied Biosystems, USA) and analysis on an ABI 3730
DNA Analyzer (Applied Biosystems; primer sequences and
PCR conditions are available on request).
As the molecular analyses performed in this study have
been performed as part of routine diagnostic daily practice,
there was no need to consulting our ethics committee. Full
disclosure of results was given to the patients, and results
were discussed in our multidisciplinary tumor board meetings
to determine the optimal treatment strategies.
RESULTS
In 112 patients (82 men and 30 women), cytologic proof
of lung cancer was obtained by EUS (n 77), EBUS (n 30),
or combined EUS and EBUS (n  5). The average age was
64.8 9.7 years (range 36–90 years). Giemsa and Papanicolaou
and immunocytochemical stainings showed squamous cell car-
cinoma in 38 cases (34%), adenocarcinoma in 35 cases (31%),
large cell or undifferentiated NSCLC in 26 patients (23%), and
small cell lung cancer in 13 cases (12%) (Table 1).
The average percentage of tumor cells in the 35 spec-
imens containing adenocarcinoma was 73%  23%. Molec-
ular analysis could not be performed in eight patients because
of insufficient material after routine cytology and immuno-
TABLE 1. Patients with EUS- or EBUS-Guided Cytology-
Proven Lung Cancer
Patient Characteristics (n  112)
Age (yr) 64.8  9.7 (range, 36–90)
Gender: female:male (n (%)) 30:82 (27:73)
Histology (n (%))
SCC 38 (34)
AC 35 (31)
LC/undifferentiated NSCLC 26 (23)
SCLC 13 (12)
Adenocarcinoma (n  35), n (%)
Samples available for analysis 27 (77)
Gender (female:male) 11:16 (41:59)
Percentage tumor cells 73%  21%
KRAS mutation positive (n (%)) 10 (37)
c.35GT (p.Gly12Val) 5
c.35GA (p.Gly12Asp) 2
c.34GT (p.Gly12Cys) 1
c.182AT (p.Glu61Leu) 1
c.37GT (p.Gly13Cys) 1
EGFR mutation positive (n (%)) 2 (7)
c.2369CT (p.Thr790Met) and
c.2573TG (p.Leu858Arg)a
1
c.2239_2248delinsC
(p.Leu747_Ala750delinsPro)
1
KRAS and EGFR mutation negative
(n (%))
15 (56)
a Double mutation in one patient.
AC, adenocarcinoma; LC, large cell undifferentiated NSCLC; NSCLC, non-small
cell lung cancer; SCLC, small cell lung cancer; SCC, squamous cell carcinoma; EGFR,
epidermal growth factor receptor.
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cytochemistry(n  3), a low percentage (40%) of tumor
cells (n  3), or an insufficient DNA quality (n  2).
Molecular analysis could reliably be performed in 27
patients (77%). The average percentage of tumor cells in the
27 samples was 79%  12%. Analysis was performed on
material obtained from cell blocks (n  19), Giemsa-stained
(n  3) or Papanicolaou-stained smears (n  5).
Mutation analysis showed KRAS mutations in tumor
samples from 10 patients (37%). Six mutations were detected
in cell block preparations and four in material from Papani-
colaou-stained smears. EGFR mutations were found in two
patients (7.4%). One patient had an activating exon 19
(p.Leu747_Ala750delinsPro) mutation detected in material
from a Papanicolaou-stained smear. The second patient, with
recurrent, TKI-naive adenocarcinoma, had two EGFR muta-
tions (p.Thr790Met and p.Leu858Arg) detected in a cell
block specimen (Table 1 and Figure 1).
DISCUSSION
This study shows that molecular analysis of EGFR and
KRAS mutations on cytologic material obtained by EUS or
EBUS is feasible and can be performed in daily practice.
Molecular analysis could be performed in 77% of the adeno-
carcinoma samples. Biomarker analysis on cytologic material
is becoming increasingly available. A far as we know, this is
the first study to report successful mutation analysis of both
the KRAS and EGFR gene on both cytologic smears and cell
blocks obtained by EUS or EBUS.
In 27 of 35 patients (77%) with cytologically proven
lung adenocarcinomas, we were able to perform molecular
analysis using PCR and subsequent sequence analysis. This is
in agreement with the study by Garcia-Olive et al.,15 where
EGFR gene analysis of the EBUS-TBNA sample was feasible
in 26 (72.2%) of the 36 patients with lymph node metastasis
and similar methods were used. Nakajima et al.16 were able to
perform molecular analysis in histologic cores obtained by
EBUS in 43 of 46 lung adenocarcinoma patients (94%). In
this study, the assessment of tumor cells is not described, but
the short axis of the sampled lymph nodes with EGFR
mutations was approximately similar to that of our study
(16.8 7.0 mm).16 The percentage of EGFRmutations found
in the aforementioned Spanish and Japanese studies was 10%
FIGURE 1. Representative sample of a 77-year-old patient referred for analysis of suspected recurrent lung cancer 4 years
after the left upper lobe resection for a pT1aN0M0 adenocarcinoma. Endobronchial ultrasound (EBUS)-guided lymph node
sampling revealed recurrent disease with a double epidermal growth factor receptor (EGFR) mutation: panel A, endosono-
graphic EBUS image of the enlarged subcarinal lymph node at position number 7 (diameter, 23.5 mm); panel B, hematoxylin
and eosin staining of lymph node aspirate (200) revealing adenocarcinoma; and panel C, sequence chromatograms of EGFR
mutations c.2369CT (p.Thr790Met) (top) and c.2573TG (p.Leu858Arg) (bottom).
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and 26%, respectively. Especially the percentage from the
latter study is much higher than the percentage of EGFR
mutations (7.4%) found in our cohort. This might reflect a
high percentage of cigarette smoking patients in our predom-
inantly male, white group of patients. Unfortunately, exact
data on smoking status are not available because the majority
of our patients were referred for the diagnostic endosono-
graphic procedure only and treated in the referring hospitals.
However, in our own clinic for thoracic oncology, approxi-
mately 87% of patients are current or former smokers.
The percentage of KRAS mutations (37%) in our cohort
is in line with other studies reporting KRASmutations ranging
from 15 to 22% and 18 to 43% in nonsmoking and smoking
subjects, respectively.4,14 Earlier studies used paraffin-em-
bedded material from cell blocks,15,16 whereas in this study,
tumor cells could also be retrieved from direct cytologic
smears. This may offer additional opportunities for mutation
analysis, especially when histologic biopsies and cell blocks
do not contain enough tumor cells.
In our feasibility study, we concentrated on the molecular
analyses of adenocarcinoma; however, the technique will also be
applicable in other histologic groups. Because the predictive
value of EGFR amplification is still under debate.18,19 Fluores-
cent in situ hybridization analysis was not routinely performed in
our samples; however, in the only cytologic sample, in which
fluorescent in situ hybridization analysis was performed, an
EGFR amplification was detected.
CONCLUSION
This study shows that molecular analysis for KRAS and
EGFR mutations can be performed routinely on cytologic
specimens from EUS- and EBUS-guided FNA. Molecular
analysis could be performed in 77% of the lung adenocarci-
nomas found in these cytologic samples. With this article, we
hope to increase awareness of these techniques and show that
also in daily clinical practice, EGFR and KRAS analysis can
be performed in a high percentage of patients.
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